Get the Stockscreener App
2.98
6.43%
0.18
After Hours:
3.01
0.03
+1.01%
Curevac N V stock is traded at $2.98, with a volume of 2.03M.
It is up +6.43% in the last 24 hours and down -2.61% over the past month.
See More
Previous Close:
$2.80
Open:
$3.29
24h Volume:
2.03M
Relative Volume:
2.57
Market Cap:
$628.15M
Revenue:
$596.48M
Net Income/Loss:
$123.72M
P/E Ratio:
5.434
EPS:
0.5484
Net Cash Flow:
$106.59M
1W Performance:
+3.11%
1M Performance:
-2.61%
6M Performance:
-0.67%
1Y Performance:
-1.65%
1-Day Range:
$2.965
$3.33
1-Week Range:
$2.78
$3.33
52-Week Range:
$2.215
$5.28
Curevac N V Stock (CVAC) Company Profile
Compare CVAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
2.98 | 628.15M | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-08-23 | Initiated | SVB Securities | Outperform |
| Jan-19-23 | Upgrade | UBS | Neutral → Buy |
| Jan-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Jun-17-21 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Underperform |
| Apr-26-21 | Initiated | Guggenheim | Neutral |
| Dec-10-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Sep-08-20 | Initiated | Credit Suisse | Neutral |
| Sep-08-20 | Initiated | Jefferies | Hold |
View All
Curevac N V Stock (CVAC) Latest News
CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions (NASDAQ:CVAC) - Seeking Alpha
CureVac (CVAC) Stock Surges After Favorable Patent Ruling - Stocks Telegraph
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps - Benzinga
Lululemon, General Motors and Apple fall premarket; CureVac gains By Investing.com - Investing.com Canada
Lululemon, General Motors and Apple fall premarket; CureVac gains - Investing.com
CureVac, gold miners, Rocket Lab - TradingView
CureVac Patent Validated in BioNTech Dispute, Infringement Hearing Set for July - Marketscreener.com
PRTG Soars On Mesothelioma Data, NVNO Awaits FDA Decision, CureVac Jumps On Patent News - RTTNews
CureVac’s amended patent upheld by European Patent Office By Investing.com - Investing.com South Africa
European Patent Office declares CureVac mRNA patent valid - Marketscreener.com
CureVac up 13% as court upholds validity of patent in BioNTech spat - Seeking Alpha
CureVac’s amended patent upheld by European Patent Office - Investing.com
Major Patent Victory: CureVac's Critical mRNA Technology Upheld Against BioNTech Challenge - StockTitan
CureVac N.V. (CVAC) Gets Positive Validity Decision In Suit Vs BioNTech (BNTX)Bloomberg - StreetInsider.com
EQS-News: CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE - Sharewise
Amundi Sells 54,048 Shares of CureVac (NASDAQ:CVAC) - Defense World
CureVac Stock: Recovery Continues Despite Weekly Fluctuations - Sharewise
CureVac N.V.'s (NASDAQ:CVAC) largest shareholders are individual investors with 38% ownership, private equity firms own 31% - Yahoo Finance UK
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet - ACCESS Newswire
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board - ACCESS Newswire
CureVac: The mid-term effect of pipeline pruning -February 21, 2025 at 08:16 am EST - Marketscreener.com
Is CureVac N.V. (CVAC) the Best Get Rich Fast Stock to Buy Now? - Insider Monkey
12 Best Get Rich Fast Stocks To Buy Now - Insider Monkey
A History of Outperforming Analyst Forecasts and Beating the Odds: CureVac N.V (CVAC) - SETE News
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators - ACCESS Newswire
mRNA Pioneer CureVac Clinches Elite Innovation Status with 1,000-Patent Arsenal - StockTitan
CureVac's SWOT analysis: mRNA pioneer's stock faces pivotal year in vaccine race - MSN
CureVac Appoints Klaus Edvardsen as Chief Development Officer - ACCESS Newswire
JMP Securities Reiterates “Market Outperform” Rating for CureVac (NASDAQ:CVAC) - Defense World
CureVac (NASDAQ:CVAC) Shares Gap UpWhat's Next? - MarketBeat
Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch (CORRECTED) - Benzinga
Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch - Benzinga
CureVac (NASDAQ:CVAC) Trading Down 5.8%Time to Sell? - MarketBeat
Individual investors among CureVac N.V.'s (NASDAQ:CVAC) largest stockholders and were hit after last week's 6.1% price drop - Simply Wall St
Moderna, CureVac, other vaccine stocks jump as new human bird-flu cases reported in U.S., Australia - MSN
CureVac NV (FRA:5CV) Altman Z-Score : 3.43 (As of Feb. 01, 2025) - GuruFocus.com
CureVac NV (FRA:5CV) Momentum Rank : 7 (As of Feb. 01, 2025) - GuruFocus.com
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - ACCESS Newswire
CureVac (NASDAQ:CVAC) Shares Sold by Ballentine Partners LLC - Defense World
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update - ACCESS Newswire
Brokers Offer Predictions for CureVac FY2025 Earnings - Defense World
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update - ACCESS Newswire
22,946 Shares in CureVac (NASDAQ:CVAC) Bought by Barclays PLC - Defense World
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024 - ACCESS Newswire
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer - ACCESS Newswire
FY2025 EPS Estimates for CureVac Raised by Leerink Partnrs - MarketBeat
Companies Like CureVac (NASDAQ:CVAC) Are In A Position To Invest In Growth - Yahoo Finance
CureVac (NASDAQ:CVAC) Stock Price Down 3.7%What's Next? - MarketBeat
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update - ACCESS Newswire
CureVac (NASDAQ:CVAC) Shares Up 4.7%Should You Buy? - MarketBeat
Bird Flu Raising Red Flags Among Health Officials, CDC Urges Faster TestingCureVac (NASDAQ:CVAC) - Benzinga
Curevac N V Stock (CVAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):